Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:HIMS NYSE:NVO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$23.98+4.1%$24.07$13.74▼$70.43$5.47B2.4332.61 million shs13.24 million shsNVONovo Nordisk A/S$44.38-1.5%$40.05$35.12▼$81.44$198.17B0.7721.32 million shs9.63 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+2.64%-4.35%-25.63%+45.67%-62.33%NVONovo Nordisk A/S+1.88%-4.36%+11.41%-7.00%-33.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHIMSHims & Hers Health$23.98+4.1%$24.07$13.74▼$70.43$5.47B2.4332.61 million shs13.24 million shsNVONovo Nordisk A/S$44.38-1.5%$40.05$35.12▼$81.44$198.17B0.7721.32 million shs9.63 million shsThe 7 Hottest IPOs On Wall Street’s 2026 WatchlistMarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHIMSHims & Hers Health+2.64%-4.35%-25.63%+45.67%-62.33%NVONovo Nordisk A/S+1.88%-4.36%+11.41%-7.00%-33.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHIMSHims & Hers Health 2.12Hold$29.3722.47% UpsideNVONovo Nordisk A/S 2.13Hold$65.5647.72% UpsideCurrent Analyst Ratings BreakdownLatest HIMS and NVO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$30.00 ➝ $28.005/13/2026HIMSHims & Hers Health Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$32.00 ➝ $30.005/12/2026HIMSHims & Hers Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C) ➝ Sell (D)5/12/2026NVONovo Nordisk A/S CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral5/12/2026HIMSHims & Hers Health Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.505/12/2026HIMSHims & Hers Health UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.005/12/2026HIMSHims & Hers Health Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$32.005/12/2026HIMSHims & Hers Health CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$24.00 ➝ $28.005/12/2026HIMSHims & Hers Health JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$35.00 ➝ $33.005/12/2026HIMSHims & Hers Health Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$30.00 ➝ $35.005/12/2026HIMSHims & Hers Health BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral(Data available from 5/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHIMSHims & Hers Health$2.37B2.31$0.89 per share26.81$1.96 per share12.23NVONovo Nordisk A/S$46.80B4.23$4.70 per share9.45$7.12 per share6.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHIMSHims & Hers Health$128.37M-$0.09N/A48.9439.59-0.56%6.10%1.52%N/ANVONovo Nordisk A/S$15.51B$4.2610.4212.863.9437.23%63.31%22.19%8/5/2026 (Estimated)Latest HIMS and NVO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/11/2026Q1 2026HIMSHims & Hers Health$0.04-$0.40-$0.44-$0.40$616.84 million$608.10 million5/6/2026Q1 2026NVONovo Nordisk A/S$0.87$1.04+$0.17$1.69$10.86 billion$10.85 billion3/31/2026Q1 2026NVONovo Nordisk A/SN/A$1.0270N/A$1.69N/A$10.85 billion2/23/2026Q4 2025HIMSHims & Hers Health$0.02$0.08+$0.06$0.08$619.48 million$617.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthHIMSHims & Hers HealthN/AN/AN/AN/AN/ANVONovo Nordisk A/S$1.753.94%+21.74%41.08%N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHIMSHims & Hers Health2.181.691.56NVONovo Nordisk A/S0.590.790.56Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHIMSHims & Hers Health63.52%NVONovo Nordisk A/S11.54%Insider OwnershipCompanyInsider OwnershipHIMSHims & Hers Health11.76%NVONovo Nordisk A/S0.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHIMSHims & Hers Health2,442227.94 million201.13 millionOptionableNVONovo Nordisk A/S69,5054.47 billion4.46 billionOptionableHIMS and NVO HeadlinesRecent News About These CompaniesHow does Lilly’s next-gen obesity drug compare to Novo’s2 hours ago | seekingalpha.comDeutsche Bank Remains a Hold on Novo Nordisk (0QIU)2 hours ago | theglobeandmail.comSemaglutide MASH Data Broadens Novo Nordisk Case For Undervalued Shares2 hours ago | finance.yahoo.comCan Mounjaro, Zepbound & Foundayo Keep Fueling LLY's Growth Story?3 hours ago | zacks.comThe Silver Lining of Last Week's Hims & Hers Earnings Miss (NVO)...4 hours ago | marketbeat.comCould Viking Therapeutics Be the Next Eli Lilly?May 21 at 8:50 AM | fool.comFortis Group Advisors LLC Grows Stake in Novo Nordisk A/S $NVOMay 21 at 7:28 AM | marketbeat.comSierra Summit Advisors LLC Purchases New Position in Novo Nordisk A/S $NVOMay 21 at 6:26 AM | marketbeat.comFocus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors sayMay 21 at 6:02 AM | reuters.comCullen Frost Bankers Inc. Has $8.52 Million Stock Holdings in Novo Nordisk A/S $NVOMay 21 at 5:53 AM | marketbeat.comBest Weight Loss Drug Stocks to Buy in 2026May 20 at 11:15 PM | fool.comFrom Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook (NVO)...May 20 at 2:55 PM | marketbeat.comAcute Myocardial Infarction Market is Expected to Hit Growth Stride at a CAGR of 13% During the Forecast Period (2026-2036) with New Therapeutic Innovations | DelveInsightMay 20 at 2:32 PM | finance.yahoo.comDenmark GDP Jumps 1.9% as Pharma Sector Drives GrowthMay 20 at 2:32 PM | finance.yahoo.comNovo Nordisk cautiously optimistic on key GLP-1 obesity study, says Deutsche BankMay 20 at 10:46 AM | proactiveinvestors.co.ukHow New Wegovy Obesity Trial Data At Novo Nordisk (CPSE:NOVO B) Has Changed Its Investment StoryMay 20 at 9:32 AM | finance.yahoo.comFY2027 Earnings Forecast for NVO Issued By Erste Group BankMay 20 at 7:06 AM | marketbeat.comNovo Nordisk’s next obesity battlefront: Winning beyond AmericaMay 19 at 6:47 PM | msn.comGLP-1 Drug Giants Race to Go Global With Their Obesity Pills: ETFs to GainMay 19 at 6:47 PM | finance.yahoo.comNovo Nordisk’s AMAZE 12 Trial: Next Wave in Obesity Maintenance DrugsMay 19 at 12:51 PM | tipranks.comNovo Nordisk Advances New Cagrilintide Study in the Race for Obesity LeadershipMay 19 at 12:51 PM | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 2026Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in FocusBy Jessica Mitacek | May 8, 2026Amazon Takes a Bite Out of Hims: What Its GLP-1 Entrance MeansBy Leo Miller | April 28, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 2026The Silver Lining of Last Week's Hims & Hers Earnings MissBy Jessica Mitacek | May 21, 2026HIMS and NVO Company DescriptionsHims & Hers Health NYSE:HIMS$23.98 +0.94 (+4.08%) Closing price 03:59 PM EasternExtended Trading$24.12 +0.15 (+0.61%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Novo Nordisk A/S NYSE:NVO$44.38 -0.69 (-1.52%) Closing price 03:59 PM EasternExtended Trading$44.37 -0.01 (-0.03%) As of 04:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Target Shows Strengths, But Analysts Want to See More Freight Boom: The Hormuz Blockade Payday TJX Companies Fires on All Cylinders With 9% Revenue Growth Analog Devices Provides Much-Needed Pullback: How Low Can It Go? USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
